El fons d'inversió Genesis Ventures, gestionat per la consultora Genesis Biomed, ha fet la seva primera inversió de 75.000 euros en el projecte de recerca NeuroHeal de l'Institut de Neurociències (INc) de la Universitat Autònoma de Barcelona (UAB) liderat per la Dra. Caty Casas. L'acord permetrà accelerar el desenvolupament del producte i avançar en la creació d'una nova spin-off.

NeuroHeal consisteix en un nou tractament de primera línia per accelerar els processos de neuroregeneració i reduir l'atròfia muscular.

Genesis Ventures, que es va presentar al Parc Científic de Barcelona el novembre de 2017, mostra la seva aposta per ...

Catalan biomedical companies attracted €102 million in investment in 2017, with €3.4 million per operation, on average. This will allow them to push forward in the development of drugs and innovative medical technology, as reflected in the Study on investment in the Biomedical industry in Catalonia: Achievements and future challenges presented today by CataloniaBio & HealthTech and EY in Barcelona. The event drew a crowd of more than 60 entrepreneurs, investors and professionals from the sector.

Venture capital continues to be the main source of funding for companies that develop products (33%), while service firms tend to opt for ...

Venture capital firm Inveready, a CataloniaBio & HealthTech member, is putting the finishing touches on a €25-million fund to invest in start-ups in the health and biotechnology arena. The fund will be launched in the coming weeks, according to information from Expansión

With this third vehicle coming soon, to be called Biotech III, Inveready will manage more than €175 million in investment. In total, they hope to build a portfolio of 20 to 25 companies, mainly in Spain. 

Photo: Sara Secall and Roger Piqué at the Inveready headquarters in Barcelona - © Expansión, Elena Ramón

Banco Sabadell and Asabys Partners, founded by Josep Lluís Sanfeliu and Clara Campàs —member of the last Board of directors at CataloniaBio (2014-2018)—, have created a new venture capital fund of 60 million euros which will centre its investment activity in the health arena.

The new fund is known as Sabadell Asabys Health Innovation Fund. It will carry out initial investments in biotech, MedTech and digital health companies in Spain, as well as the UK and Israel.

The fund could obtain up to 6 million euros per company, and expects to work closely with research centres and benchmark ...

Bionure, member of CataloniaBio & HealthTech that develops neuroprotectant agents to treat neurodegenerative diseases primarily focusing on rare ophthalmologic diseases as Acute Optic Neuritis (AON) and Neuromyelitis Optica (NMO), announces the initiation of a Phase I clinical trial of its lead compound BN201 in the United Kingdom.

BN201 is a first-in-class selective SGK2 agonist that promotes remyelination and neuroprotection, offering a game-changing solution for neurodegenerative diseases.

The company has reconstituted its Board of Directors and added prominent neuro-ophthalmologist Dr. Craig Smith as the new Chief Medical Officer (CMO). Dr Smith is a Senior Advisor/Consultant with the Bill and Melinda ...